Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

OBJECTIVE To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids. METHODS This is a 12-month extension of a previously completed 1-year trial of daily ALN, performed to evaluate the effects of ALN over a total of 2 years in 66 men and 142 women continuing to receive at least 7.5 mg of prednisone or equivalent daily. All patients received supplemental calcium and vitamin D. The primary end point was the mean percentage change in lumbar spine bone mineral density (BMD) from baseline to 24 months. Other outcomes included changes in hip and total body BMD, biochemical markers of bone turnover, radiographic joint damage of the hands, and vertebral fracture incidence. RESULTS The mean (+/-SEM) lumbar spine BMD increased by 2.8 +/- 0.6%, 3.9 +/- 0.7%, and 3.7 +/- 0.6%, respectively, in the groups that received 5 mg, 10 mg, and 2.5/10 mg of ALN daily (P < or = 0.001) and decreased by -0.8 +/- 0.6% in the placebo group (P not significant) over 24 months. In patients receiving any dose of ALN, BMD was increased at the trochanter (P < or = 0.05) and maintained at the femoral neck. Total body BMD was increased in patients receiving 5 or 10 mg ALN (P < or = 0.01). These 2 dose levels of ALN were more effective than placebo at all sites (P < or = 0.05). Bone turnover markers (N-telopeptides of type I collagen and bone-specific alkaline phosphatase) decreased 60% and 25%, respectively, during treatment with ALN (P < or = 0.05). There were fewer patients with new vertebral fractures in the ALN group versus the placebo group (0.7% versus 6.8%; P = 0.026). The safety profile was similar between treatment groups. CONCLUSION Alendronate is an effective, well-tolerated therapy for the prevention and treatment of glucocorticoid-induced osteoporosis, with sustained treatment advantages for up to 2 years.

[1]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[2]  S. Wallach,et al.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.

[3]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[4]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[5]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[6]  C. Roux,et al.  Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  P. Rottoli,et al.  Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid Patients , 1997, Calcified Tissue International.

[8]  Jacques P. Brown,et al.  Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.

[9]  Ego Seeman,et al.  Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.

[10]  E. Themeles,et al.  Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. , 1997, British journal of rheumatology.

[11]  E. Leib,et al.  Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis , 1996, Annals of Internal Medicine.

[12]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[13]  M. Pringle,et al.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study , 1996, BMJ.

[14]  S. Cummings,et al.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis , 1996 .

[15]  B. Dijkmans,et al.  Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. , 1996, Arthritis and rheumatism.

[16]  M. Krogsgaard,et al.  Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. , 1996, Annals of the rheumatic diseases.

[17]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[18]  C. Cooper,et al.  Rheumatoid arthritis, corticosteroid therapy and hip fracture. , 1995, Annals of the rheumatic diseases.

[19]  T. Spector,et al.  Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. , 1994, Arthritis and rheumatism.

[20]  D. Furst,et al.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.

[21]  D. Boumpas,et al.  Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates , 1993, Annals of Internal Medicine.

[22]  J. Eisman,et al.  Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. , 1993, The New England journal of medicine.

[23]  Joseph F. Heyse,et al.  An Empirical and Simulated Comparison of Some Tests for Detecting Progressiveness of Response with Increasing Doses of a Compound , 1992 .

[24]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.

[25]  I. Reid,et al.  PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD) , 1988, The Lancet.

[26]  H K Genant,et al.  How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? , 1985, Arthritis and rheumatism.

[27]  J W Tukey,et al.  Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.